<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20060314192922+01'00'</creation_date><modification_date>D:20060314192922+01'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-00-131_h_dec_1.pdf</pdf_file></head><body><section><header>i commission of the european communities  
  
  
  
  
  
 brussels, 
 16/11/2000    c(2000) 3227</header></section><section><header>not for publication         commission decision</header><p> of 16/11/2000</p><p> amending the marketing authorization for the</p><p>
 medicinal product</p><p>
 for human use</p></section><section><header>&quot;pegintron – peginterferon alfa-2b&quot;</header><p>(new pack size)</p><p>
 only the french and the dutch texts are authentic</p><p>
 (text with eea relevance)</p><p>ii</p></section><section><header>commission decision</header><p>of 16/11/2000</p><p> amending the marketing authorization for the</p><p>
 medicinal product</p><p>
 for human use</p></section><section><header>&quot;pegintron – peginterferon alfa-2b&quot;</header><p>(new pack size)</p><p>
 only the french and the dutch texts are authentic</p><p>
 (text with eea relevance)</p><p>
 the commission of the european communities,</p><p>
 having regard to the treaty establishing the european community,</p><p>
 having regard to council regulation (eec) no 2309/93 of 22 july 1993 laying down 
 community procedures for the authorization and supervision of medicinal products for human 
 and veterinary use and establishing a european agency for the evaluation of medicinal 
 products
 1, as amended by commission regulation (ec) no 649/98,2</p><p> having regard to commission regulation (ec) no 542/953 of 10 march 1995 concerning the examination of variations to the terms of a marketing authorization falling within the scope of 
 council regulation (eec) no 2309/93, and in particular article 5(2) thereof,</p><p>
 having regard to the applications to amend the marketing authorization issued by commission 
 decision on 25 may 2000 concerning the medicinal product</p></section><section><header>&quot;pegintron – peginterferon alfa-2b&quot;</header><p>entered in the community register of medicinal products under nos eu/1/00/131/001-025, submitted on 17 july 2000 under article 4(1) of the said commission regulation,</p><p>
 having regard to the favourable opinions of the european agency for the evaluation of medicinal 
 products, delivered on 10 august 2000, 11 august 2000 by the committee for proprietary medicinal 
 products,</p><p>
 whereas: 
 (1) medicinal product</p></section><section><header>&quot;pegintron – peginterferon alfa-2b&quot;</header><p> meets the requirements of council directives 65/65/eec,
 4 75/318/eec5 and 75/319/eec,6 as last amended by directive 93/39/eec;7</p><p>1</p><p>oj no l 214, 24. 8. 1993, p. 1. 2</p><p>oj no l 88, 24.3.1998, p. 7. 3 oj l 55, 11.3.1995, p.15. 4 oj 22, 9.2.1965, p. 369/65. 5 oj l 147, 9.6.1975, p. 1. 6 oj l 147, 9.6.1975, p. 13. 7 oj l 214, 24.8.1993, p. 22.</p><p>iii (2) the measures provided for in this decision fall within the notification procedure applicable to minor variations as defined in article 3(1)(a) of commission regulation (ec) no 542/95,</p><p>
 (3) in accordance with article 5(2) of commission regulation (ec) no 542/95, this decision shall 
 take effect retroactively on the 31st day following receipt by the european agency for the evaluation 
 of medicinal products of the applications for variations relating to it.</p><p>
 (4) decision c(2000)1407 of 25 may 2000 authorising the placing on the market of the medicinal 
 product</p></section><section><header>&quot;pegintron – peginterferon alfa-2b&quot;</header><p> should therefore be amended,</p><p>
 has adopted this decision:</p><p>
 article 1</p><p>
 decision c(2000)1407 is hereby amended as follows:</p><p>
 (a) -</p></section><section><header>article 1 is completed by</header><p> :</p><p>
 eu/1/00/131/026 - pegintron - 50 micrograms - powder and solvent for solution for injection - 
 subcutaneous use - powder: vial (glass),solvent: ampoule (glass) - 12 vials 
 + 12 ampoules + 12 injection sets</p><p>
 eu/1/00/131/027 -pegintron - 80 micrograms - powder and solvent for solution for injection - 
 subcutaneous use - powder: vial (glass),solvent: ampoule (glass) - 12 vials 
 + 12 ampoules + 12 injection sets</p><p>
 eu/1/00/131/028 -pegintron - 100 micrograms - powder and solvent for solution for injection - 
 subcutaneous use - powder: vial (glass),solvent: ampoule (glass) - 12 vials 
 + 12 ampoules + 12 injection sets</p><p>
 eu/1/00/131/029 -pegintron - 120 micrograms - powder and solvent for solution for injection - 
 subcutaneous use - powder: vial (glass),solvent: ampoule (glass) - 12 vials 
 + 12 ampoules + 12 injection sets</p><p>
 eu/1/00/131/030 -pegintron - 150 micrograms - powder and solvent for solution for injection - 
 subcutaneous use - powder: vial (glass),solvent: ampoule (glass) - 12 vials 
 + 12 ampoules + 12 injection sets</p><p>
 (b) - 
 annex i (summary of product characteristics) is replaced by annex i to this decision;</p><p>
 (c) - 
 annex iii (labelling and package leaflet) is replaced by annex ii to this decision.</p><p>
 article 2</p><p>
 this decision shall apply from 18 august 2000.</p><p>
 article 3</p><p>ivthis decision is addressed to sp europe,73, rue de stalle , b-1180 brussels , belgium. .</p><p>
 done at brussels, 
 16/11/2000</p><p>
 for the commission</p><p>
 ekki</p><p>liikanen</p><p>
 member of the commission</p></section></body></xml>